Literature DB >> 19169955

Diplomatic immunity: turning a foe into an ally.

Kelley A Parato1, Brian D Lichty, John C Bell.   

Abstract

Striking a balance between subversion of antiviral immune responses and enhancement of potentially therapeutic, antitumor cytotoxic responses is a challenge at the forefront of oncolytic virus (OV) research. Some of the immune hurdles that must be overcome to maximize OV delivery to spread throughout tumor beds, and an outline of some of the strategies developed to deal with these obstacles are reviewed. In addition, current research that may lead to antitumor immunity during, or subsequent to, OV therapy is discussed. Finally speculations are made upon emerging areas of viral and immune research that could be merged to create new therapeutic paradigms.

Entities:  

Mesh：

Year:  2009        PMID： 19169955

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  16 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

Review 2.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

3.  Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.

Authors:  Chunsheng Liu; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2010-03-16       Impact factor: 11.454

4.  Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.

Authors:  Timothy Kottke; John Chester; Elizabeth Ilett; Jill Thompson; Rosa Diaz; Matt Coffey; Peter Selby; Gerard Nuovo; Jose Pulido; Debabrata Mukhopadhyay; Hardev Pandha; Kevin Harrington; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 11.454

5.  Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

Authors:  Omar D Perez; Christopher R Logg; Kei Hiraoka; Oscar Diago; Ryan Burnett; Akihito Inagaki; Dawn Jolson; Karin Amundson; Taylor Buckley; Dan Lohse; Amy Lin; Cindy Burrascano; Carlos Ibanez; Noriyuki Kasahara; Harry E Gruber; Douglas J Jolly
Journal:  Mol Ther       Date:  2012-05-01       Impact factor: 11.454

6.  Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.

Authors:  Xinping Fu; Armando Rivera; Lihua Tao; Xiaoliu Zhang
Journal:  Mol Ther       Date:  2012-06-12       Impact factor: 11.454

7.  PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.

Authors:  Mulu Z Tesfay; Amber C Kirk; Elizabeth M Hadac; Guy E Griesmann; Mark J Federspiel; Glen N Barber; Stephen M Henry; Kah-Whye Peng; Stephen J Russell
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

8.  Antibody neutralization of retargeted measles viruses.

Authors:  Patrycja J Lech; Roland Pappoe; Takafumi Nakamura; Gregory J Tobin; Peter L Nara; Stephen J Russell
Journal:  Virology       Date:  2014-03-14       Impact factor: 3.616

9.  Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

Authors:  Jiqing Zhang; Lee-Hwa Tai; Carolina S Ilkow; Almohanad A Alkayyal; Abhirami A Ananth; Christiano Tanese de Souza; Jiahu Wang; Shalini Sahi; Lundi Ly; Charles Lefebvre; Theresa J Falls; Kyle B Stephenson; Ahmad B Mahmoud; Andrew P Makrigiannis; Brian D Lichty; John C Bell; David F Stojdl; Rebecca C Auer
Journal:  Mol Ther       Date:  2014-04-03       Impact factor: 11.454

10.  Is the immune response a friend or foe for viral therapy of glioma?

Authors:  Hideho Okada; Stephen H Thorne
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.